Advertisement
Advertisement
U.S. Markets close in 5 hrs 8 mins
Advertisement
Advertisement
Advertisement
Advertisement

Ovid Therapeutics Inc. (OVID)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
3.0600+0.0200 (+0.66%)
As of 09:59AM EST. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close3.0400
Open3.0400
Bid3.0500 x 900
Ask3.0600 x 1000
Day's Range3.0400 - 3.0800
52 Week Range2.5000 - 4.8000
Volume10,731
Avg. Volume210,243
Market Cap208.362M
Beta (5Y Monthly)1.70
PE Ratio (TTM)1.66
EPS (TTM)1.8390
Earnings DateMar 14, 2022 - Mar 18, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.50
  • Simply Wall St.

    Is Ovid Therapeutics Inc.'s (NASDAQ:OVID) Latest Stock Performance Being Led By Its Strong Fundamentals?

    Ovid Therapeutics' (NASDAQ:OVID) stock is up by 4.7% over the past month. Since the market usually pay for a company’s...

  • Benzinga

    Ovid Therapeutics Expands Its Anti-Epileptic Franchise With AstraZeneca Licensing Pact

    Ovid Therapeutics Inc (NASDAQ: OVID) has entered into an exclusive license agreement with AstraZeneca plc (NASDAQ: AZN) for a library of early-stage small molecules targeting the KCC2 transporter, including a lead candidate, OV350. The Company seeks to optimize and accelerate the development of these KCC2 transporter activators in epilepsies and potentially other neuropathic conditions. Under the agreement terms, AstraZeneca will receive an upfront payment of $5 million in cash and $7.5 million

  • GlobeNewswire

    Ovid Therapeutics Expands Epilepsy Franchise with Novel KCC2 Activators

    Exclusive license from AstraZeneca adds a unique candidate and a broad library of compounds to Ovid’s franchise of potential first-in-class anti-epileptic therapiesCollaboration with Dr. Stephen Moss, founder of Tufts Laboratory for Basic and Translational Neuroscience Research, and expert team in neuropharmacologyTransaction is the first business development activity that seeks to enhance Ovid’s pipeline of small-molecule and genetic CNS medicines NEW YORK, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Ovi

Advertisement
Advertisement